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Piroxicam, an oxicam derivative, is a nonsteroidal anti-inflammatory drug (NSAID).
It has anti-inflammatory, analgesic, and antipyretic properties. Piroxicam can be taken
orally to treat inflammatory diseases such as rheumatoid arthritis and osteoarthritis, mu-
sculoskeletal disorders or postoperative pain (1). Chemically, piroxicam is 4-hydroxy-2-
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Piroxicam is a nonsteroidal anti-inflammatory drug with
low aqueous solubility which exhibits polymorphism. The
present study was carried out to develop polymorphs of
piroxicam with enhanced solubility and dissolution rate
by the crystal modification technique using different sol-
vent mixtures prepared with PEG 4000 and PVP K30. Phy-
sicochemical characteristics of the modified crystal forms
of piroxicam were investigated by X-ray powder diffrac-
tometry, FT-IR spectrophotometry and differential scan-
ning calorimetry. Dissolution and solubility profiles of
each modified crystal form were studied and compared
with pure piroxicam. Solvent evaporation method (me-
thod I) produced both needle and cubic shaped crystals.
Slow crystallization from ethanol with addition of PEG
4000 or PVP K30 at room temperature (method II) pro-
duced cubic crystal forms. Needle forms produced by
method I improved dissolution but not solubility. Cubic
crystals produced by method I had a dissolution profile
similar to that of untreated piroxicam but showed better
solubility than untreated piroxicam. Cubic shaped crys-
tals produced by method II showed improved dissolu-
tion, without a significant change in solubility. Based on
the XRPD results, modified piroxicam crystals obtained
by method I from acetone/benzene were cube shaped,
which correlates well with the FTIR spectrum; modified
needle forms obtained from ethanol/methanol and etha-
nol/acetone showed a slight shift of FTIR peak that may
be attributed to differences in the internal structure or
conformation.
Keywords: piroxicam, polymorphism, crystallization, poly-
mer, dissolution
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-methyl-N-(2-pyridyl)-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide. The molecular stru-
cture of piroxicam is shown in Fig. 1. It has the molecular formula C15H13N3O4S and rela-
tive molecular mass 331.3. Piroxicam is acidic, sparingly soluble in water, slightly soluble
in alcohol and alkaline aqueous solutions and soluble in methylene chloride (1). Piroxi-
cam belongs to the biopharmaceutical classification system class II drugs of low aqueous
solubility and high permeability (2). After oral administration, it takes about 3 to 5 hours
for piroxicam to reach its peak plasma concentration (1). This shows that there is poor
absorption after oral administration. Drugs with limited aqueous solubility have slow
dissolution in biological fluid; low and erratic bioavailability leads to sub-optimal effi-
cacy in patients. Crystal engineering is an approach that may improve solubility, disso-
lution rate and bioavailability of crystalline drugs.
Polymorphism means that a chemical substance can exist in different crystal forms.
A crystalline drug can have different polymorphic forms if crystallized under different
conditions. Polymorphs can have different physical properties, such as solubility and di-
ssolution characteristics. Crystals of higher free energy will have higher solubility. This
is because molecules in crystals with high energy have weaker solid-solid interactions
and higher affinity for the solvent in the surroundings compared to crystals with lower
energy (3).
In our previous studies, the dissolution rate and solubility of dipyridamole were tes-
ted using solvents such as methanol, benzene, acetonitrile with the addition of polymers
such as Tween-80, Povidone K30 and PEG 4000 into the solvent for crystal modification
(1). It was found that the newly developed crystals had a higher dissolution rate than
the pure drug. According to other published studies, polymers such as polyethylene glycol
(PEG) and polyvinylpyrrolidone (PVP) have been used as excipients for the purpose of
improving the dissolution rate of many poorly water-soluble drugs such as NSAIDs (4, 5).
The present study has been designed to improve the solubility and dissolution rate
of piroxicam by the crystal modification technique using different solvent mixtures and
addition of different polymers into the solvent system.
EXPERIMENTAL
Materials
Piroxicam was obtained from CCM Pharmaceuticals Malaysia Berhad (Malaysia).
Solvents used were of analytical grade and were obtained from Merck, Germany. The
polymers, polyethylene glycol (PEG) 4000 and Povidone (PVP) K30, were purchased
from Sigma-Aldrich Chemie GmbH (Germany) and Sigma-Aldrich (USA), respectively.
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N Fig. 1. Chemical structure of piroxicam.
Development of piroxicam crystals
Modified crystal forms of piroxicam were prepared by the solvent evaporation and
slow crystallization method. In the solvent evaporation method, piroxicam was recry-
stallized from solvent mixtures made up of two solvents at a ratio of 1:1. Various solvent
mixtures used were ethanol/methanol, ethanol/acetone, acetone/benzene and chloro-
form/acetone. In the slow crystallization method, ethanol was used as solvent and the
polymers employed were PEG 4000 and PVP K30 at a concentration of 2 and 5 %.
Method I. – For the solvent evaporation method, 0.75 g of piroxicam was dissolved
in 50 mL of solvent mixture (25 mL of each solvent). The solution was heated till the
drug dissolved. The solution was cooled to room temperature until the solvent evapo-
rated completely. Crystals formed were dried under vacuum at room temperature and
stored in a desiccator for further use (6).
Method II. – For the slow crystallisation method (method II), 0.75 g of piroxicam was
dissolved in 50 mL of ethanol by heating and stirring continued until the whole drug
dissolved. The drug solution was filtered to remove impurities and concentrated by hea-
ting. An equal amount of polymer was rapidly added into the concentrated solution under
mild stirring for 2 minutes at room temperature (23–24 °C). The resultant crystals were
washed, recovered by vacuum filtration and then stored in a desiccator for further use.
Characterization of piroxicam crystals
Powder X-ray diffraction (XRPD). – Powder X-ray powder diffraction study was per-
formed using a D8 Advance Bruker AXS (Germany). Samples were placed in a sample
holder and scanned in the diffraction angle range (2q) between 2 and 25°. Radiation was
generated by a Cu Ka filter at a wavelength of 1.5406 Å. Diffractograms were run at 40 kV
and 40 mA current.
Scanning electron microscopy (SEM). – Samples were mounted on metal stubs using
double adhesive tape and were coated under vacuum with platinum at 5–10 mA, 1.0 kV
using a Polaron SC 7640 sputter coater in an argon atmosphere prior to observation. Ele-
ctron micrographs of the samples were obtained using a scanning electron microscope
(Phillips XL30S FEG, USA).
Melting point determination. – Melting point of piroxicam and its modified forms was
determined by the capillary method.
Differential scanning calorimetry (DSC). – Thermal analysis was performed on samples
using a thermal analysis system (Mettler-Toledo DSC 823e, Switzerland). Sample (5 mg)
was weighed into an aluminium pan and sealed. Thermograms of samples were obtai-
ned at a scanning rate of 10 °C min–1 over a temperature range of 30–275 °C under a ni-
trogen atmosphere. A similar empty pan was used as reference.
Fourier transform infrared (FTIR) spectroscopy. – The sample (1 mg) was compressed
into a disc with 100 mg dried potassium bromide. Discs were examined using an FTIR
spectrophotometer (Shimadzu, FTIR-8400S, Japan) and a spectrum between 400–4000 cm–1
was recorded.
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Solubility studies. – Solubility studies of piroxicam and its modified crystal forms were
carried out in buffer pH 1.2. Five mg of each sample was weighed into vials containing
15 mL of buffer pH 1.2. The vials were shaken at 100 rpm at 25 °C for 24 h. Samples were
analyzed for piroxicam concentration at 333 nm using a UV spectrophotometer (Jasco,
V-530, Japan).
Dissolution studies. – Dissolution studies of piroxicam and its modified forms were con-
ducted using a USP type Apparatus II (paddle apparatus) (SR8 PLUS, Hanson Research,
Canada) (15). Twenty mg of sample was added to 900 mL of buffer pH 1.2 at 37 ± 5 °C.
Paddle rotation speed was maintained at 50 rpm. In all experiments, 5 mL of dissolution
sample was withdrawn at selected time intervals and replaced with an equal volume of
fresh medium of 37 ± 0.5 °C. Samples were assayed at 333 nm.
RESULTS AND DISCUSSION
XRPD patterns of different samples of piroxicam crystallized by method I are shown
in Fig. 2. According to the diffraction patterns observed, piroxicam crystallized from ac-
etone/benzene in cube shaped crystals whereas crystallization from ethanol/methanol,
ethanol/acetone and chloroform/acetone mixtures yielded needle shaped crystals (7).
The diffraction pattern obtained for modified crystal forms of piroxicam obtained
using method II are also shown in Fig. 2. The diffraction pattern of recrystallized piro-
xicam corresponds to cube shaped crystals. Absence of PEG 4000 and PVP K30 amor-
phous peaks in the XRPD spectra was observed.
Morphology of crystals obtained from different solvent mixtures is shown in Fig. 3.
All modified forms obtained by method I have different morphology compared to un-
treated piroxicam (Fig. 3a). Piroxicam appears to have an uneven surface, which may be
due to agglomeration or aggregation of piroxicam powder. Modified forms obtained by
method I were needle-shaped with a smooth surface, except for piroxicam crystallized
from the acetone/benzene mixture (Fig. 3d) which had a rough and uneven surface.
Crystal habit can be affected during the crystallization process by factors such as polar-
ity of the crystallization solvent used (8).
According to Mihali} et al. (9), piroxicam appears to be in cube shaped crystal and
in needle forms when it is precipitated by fast cooling. Similar results were obtained in
the present study; scanning electron micrographs of piroxicam recrystallized using me-
thod II are also shown in Fig. 3. Recrystallised piroxicam had different morphology
from that of untreated piroxicam (Fig. 3a). All the modified crystal forms of piroxicam
obtained by method II majorly comprised cube shaped crystals having flat surfaces
and straight edges along with some needle recrystallized piroxicam.
Water soluble polymers, PEG 4000 and PVP K30, were added during the recrystalli-
zation process in method II. From Figs. 3f-i it follows that piroxicam recrystallized by
method II was precipitated as a cube shaped crystal. This indicates that the polymers
were laid on the surface of the cubic crystal instead of being incorporated into it. It was
difficult to distinguish the polymer from piroxicam crystals and their size using the scan-
ning electron microscope. The presence of the polymer cannot be visualized using scan-
ning electron microscope. Polymer probably affects the crystal size which forther influ-
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ences the physical properties such as dissolution and solubility. Thus the particle size
analysis of piroxicam recrystallized from the different polymers at different concentra-
tions can be investigated.
Melting point
According to the literature, piroxicam exists in two inter-convertible crystal poly-
morphs where the needle form has lower melting point of 196–198 °C and the cube sha-
ped crystal has higher melting point of 199–201 °C.
Modified crystal forms of piroxicam obtained by method II had melting points ran-
ging from 200–203 °C. This data corresponds well with the XRPD data, which shows that
piroxicam and all the modified crystal forms of piroxicam are cube shaped crystals. Mo-
dified forms of piroxicam produced by method I (ethanol/methanol and chloroform/ac-
etone) had a lower melting point than untreated piroxicam, suggesting that they are in
needle form.
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Fig. 2. Powder X-ray diffraction
of piroxicam crystallized from:
a) ethanol/methanol, b) etha-
nol/acetone, c) acetone/benze-
ne, d) chloroform/acetone; pi-
roxicam recrystallized from et-
hanol using e) PEG 4000 2 %,
f) PEG 4000 5 %, g) PVP K30 2
% and h) PVP K30 5 %.
DSC
DSC thermograms of piroxicam and its modified forms obtained by method I are
shown in Fig. 4. The thermograms are similar. Piroxicam with a melting peak of 201.89 °C
is in the cube shaped crystal. Piroxicam crystallized from ethanol/methanol, ethanol/
acetone and chloroform/acetone had a slightly lower melting point compared to piroxi-
cam, which suggests that they are in needle form. DSC thermogram of piroxicam crystalli-
zed from ethanol/acetone and chloroform/acetone showed that there may be a precipi-
tation of a stable form with higher melting point from a form with a lower melting point.
The DSC thermograms of all modified crystal forms obtained by method II were
identical with that of untreated piroxicam. There was a prominent endothermic peak in
DSC thermograms at about 200–203 °C for all recrystallized piroxicam and untreated pi-
roxicam samples, which corresponds to the melting point of the drug. There are no en-
dotherm peaks of PEG 4000 and PVP K30 in the DSC thermograms. This may indicate
that the polymers were not incorporated during crystallization.
FTIR
Based on the literature, piroxicam exists in two interconvertible crystal polymorph
needle forms that have –NH and –OH stretching bonds at 3385 cm–1 and a cube shaped
crystal with a stretching bond at 3330 cm–1. There are only small differences in the fin-
gerprint region, allowing comparison of crystal forms to be done in the region 2500 to
4000 cm–1. Fig. 5a shows an absorption band at 3338 cm–1 that indicates the cube shaped
crystal of piroxicam (9).
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Fig. 3. Scanning electron micrographs of: a) untreated piroxicam; piroxicam crystallized from b)
ethanol/methanol; c) ethanol/acetone; d) acetone/benzene; e) chloroform/acetone; f) piroxicam
recrystallized from ethanol solvent using PEG 4000 2 %; g) PEG 4000 5 %; h) PVP K30 2 %; i) PVP
K30 5 %.
Based on the XRPD results, modified piroxicam from acetone/benzene is in the
cube shaped crystal. From the FTIR spectrum in Fig 5c, it has a peak at 3338 cm–1, which
correlates well with the cube shaped crystal in the literature (9). Modified needle forms
obtained from ethanol/methanol and ethanol/acetone had a peak at 3393 cm–1. There is
a slight shift in the peak for needle crystals compared to literature data (9). From XRPD,
piroxicam crystallized from chloroform/acetone is needle-shaped and in the FTIR spec-
trum peaks are observed at 3393 and 3338 cm–1, but shows only a peak at 3393 cm–1
which may possibly be attributed to the difference in the internal structure or conformation.
For piroxicam recrystallized from method II, all the spectra are identical to the un-
treated form of piroxicam. It is shown that all the samples have a sharp absorption at
3338 cm–1. This indicates that recrystallized piroxicam is present as a cube shaped crys-
tal. These IR spectra correspond well to the XRPD, SEM, melting points and DSC data.
FTIR spectroscopic analysis can be used to analyze the possible interaction between
the drug and polymers. Figs. 5f–i show the IR-spectra of recrystallized piroxicam using
method II. Absence of PEG 4000 and PVP K30 peaks was observed in the spectra of all
samples. From the chemical structure of these polymers, hydroxyl groups of PEG 4000
and each pyrrolidone moiety of PVP exhibiting two groups (>N– and C=O) can be po-
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Fig. 4. Differential scanning calo-
rimetric thermographs of: a) un-
treated piroxicam; b) piroxicam
crystallized from ethanol/meth-
anol; c) ethanol/acetone; d) ace-
tone/benzene; e) chloroform/ac-
etone; piroxicam recrystallized
from ethanol solvent using: f)
PEG 4000 2 %; g) PEG 4000 5 %;
h) PVP K30 2 %; i) PVP K30 5 %.
tentially hydrogen bonded with the amide (N-H) group or protonated pyridine N atom
of piroxicam (10). Theoretically, there can be a chemical interaction between the drug
and polymers. However, the spectra of all samples were identical and do not show any
alteration in absorption bands. Therefore, these results suggest that there was no interac-
tion between piroxicam and polymers during crystallization.
Solubility and dissolution studies
Dissolution is primarily dependent on the solubility of a drug substance and a com-
pound with aqueous solubility lower than 0.1 mg mL–1 often exerts dissolution limita-
tions to absorption (2). Piroxicam is practically insoluble and shows two pKa values
(pKa1 = 1.86 and pKa2 = 5.46) (2).
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Fig. 5. FTIR spectra of: a) untreated piroxicam; b) piroxicam crystallized from ethanol/methanol; c)
ethanol/acetone; d) acetone/benzene; e) chloroform/acetone; piroxicam recrystallized from etha-
nol solvent using: f) PEG 4000 2 %; g) PEG 4000 5 %; h) PVP K30 2 %; i) PVP K30 5 %.
Solubility test on piroxicam and its modified forms was carried after 3 and 24 hours.
From Table I, untreated piroxicam has higher solubility after 3 hours compared to 24 hours.
This is also observed in all the modified forms of piroxicam except for piroxicam crystal-
lized by method I using an acetone/benzene mixture. Reduction in solubility from 3 to
24 hours may be due to the change in the form of the crystal in the medium. A meta-
stable form can convert to a more stable form leading to reduced solubility. Piroxicam
crystallized from acetone/benzene had slightly lower solubility after 3 hours but sho-
wed improvement in solubility at 24 hours. This may be due to the stable form, which is
resistant to conversion to another form.
Dissolution profile of piroxicam and its modified forms is shown in Figs. 6a and b.
The 3-hour solubility profile of modified forms of piroxicam is reflected in dissolution
results where all samples have a better dissolution profile than untreated piroxicam ex-
cept for piroxicam crystallized from the acetone/benzene mixture using method I. The
most prominent improvement in dissolution was obtained using modified crystal forms
of piroxicam oftained by method II using ethanol as the solvent with 5 % PVP K30. It
showed about 2-fold increase in dissolution; this means that 99.8 % of the drug dissol-
ved compared to 56.8 % of untreated piroxicam dissolved after 3 hours. There was also
an increase in dissolution with increasing polymer concentration. At higher polymer con-
centration, which is 5 % for PEG 4000 and PVP K30, the dissolution profile of recrystalli-
zed piroxicam using ethanol solvent at room temperature increased from 85.7 to 93.5 %
and 94.6 to 99.8 %, respectively.
Needle forms produced by method I and cube shaped crystals obtained by method
II showed improved dissolution but not solubility. Cubic crystals produced by method I
havea dissolution profile similar to that of untreated piroxicam and better solubility.
Dissolution results also contradict the solubility results in 24 hours. Samples with
good dissolution have poor solubility after 24 hours and vice versa. This phenomenon
could be attributed to the negative nature of Gibbs free energy changes and spontaneity
of the process (12, 14). Therefore, all the modified crystal forms of piroxicam with good
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Table I. Melting points, solubility after three hours and twenty-four hours for untreated piroxicam and





3 hours 24 hours
Untreated piroxicam 200–203 97.732 88.757
Piroxicam crystallized from
Ethanol/methanol 197–199 134.911 68.935
Ethanol/acetone 200–203 134.615 70.118
Acetone/benzene 200–203 96.351 107.990
Chloroform/acetone 199–201 125.542 75.345
Ethanol/PEG4000 (2 %) 201–204 91.519 136.031
Ethanol/PEG4000 (5 %) 202–205 95.069 143.527
Ethanol/PVP K30 (2 %) 200–203 92.110 94.014
Ethanol/PVP K30 (5 %) 200–203 90.927 114.310
dissolution have low solubility after 24 hours due to the transformation to a stable form
with low solubility, except for piroxicam crystallized from acetone/benzene using method I.
Piroxicam is almost insoluble in water and hence remains floating on the surface of
the dissolution medium due to poor contact with the medium thereby resulting in a poor
dissolution profile. Difference in the dissolution and solubility profile of the modified
piroxicam can be due to the difference in crystal structure. Solvents with varying polari-
ties and desolvation process affect crystal formation, leading to different morphologies
and properties of crystals obtained from different solvent mixtures (3).
Crystallization process is also affected by the choice of additives (4, 8, 11, 12). Addi-
tion of PEG 4000 and PVP K30 during recrystallization influenced the dissolution rate.
400

















































ethanol/PVP K30 (2 %)
ethanol/PVP K30 (5 %)
b)
Fig. 6. Dissolution profile of: a) untreated piroxicam and modified forms of piroxicam crystallized
from various solvent mixtures, b) modified crystals crystallized by the slow recrystallization me-
thod with incorporation of polymer. Mean ± SD, n = 3.
According to physicochemical characterization, piroxicam and piroxicam recrystallized
using method II are in cube shaped crystals. However, recrystallized piroxicam displa-
yed a better dissolution profile than the untreated form of piroxicam. The differences are
due to the use of water-soluble hydrophilic polymers (4, 8) forming a hydrophilic film
on the surface of drug crystals, increasing the drug wettability and preventing drug ag-
gregation, changing the crystallinity of piroxicam and giving rise to a form with a better
dissolution rate (4, 11, 10, 13).The presence of additives during the crystallization pro-
cess might also cause a defect in the crystal structure and the crystal would become ther-
modynamically unstable and hence dissolve faster.
CONCLUSIONS
In conclusion, modification of piroxicam by evaporation from different solvent mix-
tures and incorporation of a polymer resulted in formation of different crystal forms.
Needle forms produced from solvent evaporation had improved dissolution but not solu-
bility while cube shaped crystals produced from solvent evaporation had a similar dis-
solution profile and better solubility than untreated piroxicam. Cube shaped crystals
produced by the slow crystallization method with addition of a polymer had improved
dissolution but not solubility. For future studies, single crystallographic studies can be
carried out to further examine the single crystal structure.
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S A @ E T A K
Kristalne modifikacije i profil osloba|anja piroksikama
LIM YEE LYN, HUAN WEN SZE, ADHIYAMAN RAJENDRAN, GORAJANA ADINARAYANA, KAMAL DUA i SANJAY GARG
Piroksikam je nesteroidni protuupalni lijek male topljivosti u vodi koji ima svojstvo
polimorfije. Cilj rada bio je priprema polimorfa piroksikama pove}ane topljivosti i brzi-
ne osloba|anja koriste}i smjese razli~itih otapala i PEG 4000, odnosno PVP K30. Fiziko-
kemijska svojstva modificiranih kristalnih oblika piroksikama ispitivana su difrakcijom
X-zraka na pra{kastom uzorku FT-IR spektrofotometrijom i diferencijalnom pretra`nom
kalorimetrijom. Profili osloba|anja i topljivosti modificiranih kristalnih oblika prou~ava-
ni su i uspore|ivani sa ~istim piroksikamom. Metodom uparavanja otapala (metoda I)
dobiveni su igli~asti i kubi~ni kristali. Polaganom kristalizacijom iz etanola uz dodatak
PEG 4000 ili PVP K30 na sobnoj temperaturi (metoda II) dobiveni su kubi~ni kristali.
Igli~asti kristali dobiveni metodom I pobolj{ali su osloba|anje, ali ne i topljivost. Kubi-
~ni kristali dobiveni metodom I imali su pobolj{anu topljivost, ali sli~an profil osloba|a-
nja kao i netretirani piroksikam. Kubi~ni kristali dobiveni metodom II imali su pobolj-
{ani profil osloba|anja, bez zna~ajne promjene u topljivosti. Na temelju XRPD rezultata,
modificirani kristali piroksikama dobiveni metodom I iz smjese acetona i benzena bili su
kubi~ni, {to dobro korelira s FTIR spektrom; modificirani igli~asti kristali dobiveni iz
smjese etanol/metanol i etanol/aceton imali su lagani pomak FTIR signala {to bi se mo-
glo pripisati razlikama u internoj strukturi ili konformacijama.
Klju~ne rije~i: piroksikam, polimorfizam, kristalizacija, polimer, osloba|anje
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